Author

Marijn C. Visschedijk

SUPERIOR EFFECTIVENESS OF TOFACITINIB COMPARED TO VEDOLIZUMAB IN ANTI-TNF EXPERIENCED ULCERATIVE COLITIS PATIENTS: A NATIONWIDE DUTCH REGISTRY STUDY
SUPERIOR EFFECTIVENESS OF TOFACITINIB COMPARED TO VEDOLIZUMAB IN ANTI-TNF EXPERIENCED ULCERATIVE COLITIS PATIENTS: A NATIONWIDE DUTCH REGISTRY STUDY

Marijn C. Visschedijk  et al.

MICRORNAS ARE POTENTIAL EARLY MARKERS OF COELIAC DISEASE AND MAY REGULATE THE COELIAC DISEASE-SPECIFIC TRANSCRIPTIONAL CHANGES IN THE SMALL INTESTINE
MICRORNAS ARE POTENTIAL EARLY MARKERS OF COELIAC DISEASE AND MAY REGULATE THE COELIAC DISEASE-SPECIFIC TRANSCRIPTIONAL CHANGES IN THE SMALL INTESTINE

Marijn C. Visschedijk  et al.

PROTEOMIC ANALYSES DO NOT REVEAL SUBCLINICAL INFLAMMATION IN FATIGUED PATIENTS WITH QUIESCENT INFLAMMATORY BOWEL DISEASE
PROTEOMIC ANALYSES DO NOT REVEAL SUBCLINICAL INFLAMMATION IN FATIGUED PATIENTS WITH QUIESCENT INFLAMMATORY BOWEL DISEASE

Marijn C. Visschedijk  et al.

THE EFFECT OF INDUCTION THERAPY WITH INFLIXIMAB OR VEDOLIZUMAB ON HEPCIDIN AND IRON STATUS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
THE EFFECT OF INDUCTION THERAPY WITH INFLIXIMAB OR VEDOLIZUMAB ON HEPCIDIN AND IRON STATUS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Marijn C. Visschedijk  et al.

TYPE IV COLLAGEN FORMATION/DEGRADATION RATIO PREDICTS RESPONSE TO INFLIXIMAB INDUCTION THERAPY IN PATIENTS WITH ULCERATIVE COLITIS
TYPE IV COLLAGEN FORMATION/DEGRADATION RATIO PREDICTS RESPONSE TO INFLIXIMAB INDUCTION THERAPY IN PATIENTS WITH ULCERATIVE COLITIS

Marijn C. Visschedijk  et al.

INVESTIGATION OF SOMATIC MUTATIONS IN BIOPSIES FROM PATIENTS WITH INFLAMMATORY BOWEL DISEASE
INVESTIGATION OF SOMATIC MUTATIONS IN BIOPSIES FROM PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Marijn C. Visschedijk  et al.

BIOMARKERS OF EXTRACELLULAR MATRIX TURNOVER AND NEUTROPHIL ACTIVITY PREDICT LONG-TERM RESPONSE TO VEDOLIZUMAB IN PATIENTS WITH CROHN’S DISEASE
BIOMARKERS OF EXTRACELLULAR MATRIX TURNOVER AND NEUTROPHIL ACTIVITY PREDICT LONG-TERM RESPONSE TO VEDOLIZUMAB IN PATIENTS WITH CROHN’S DISEASE

Marijn C. Visschedijk  et al.

TYPE I COLLAGEN DEGRADATION FRAGMENTS (C1M) AND HUMAN NEUTROPHIL ELASTASE-DERIVED FRAGMENTS OF CALPROTECTIN (CPA9-HNE) REFLECT BIOCHEMICAL AND ENDOSCOPIC DISEASE ACTIVITY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES
TYPE I COLLAGEN DEGRADATION FRAGMENTS (C1M) AND HUMAN NEUTROPHIL ELASTASE-DERIVED FRAGMENTS OF CALPROTECTIN (CPA9-HNE) REFLECT BIOCHEMICAL AND ENDOSCOPIC DISEASE ACTIVITY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES

Marijn C. Visschedijk  et al.

TYPE I, III, AND IV COLLAGEN DEGRADATION FRAGMENTS AND THE TYPE IV COLLAGEN FORMATION/DEGRADATION RATIO ARE SEROLOGICAL BIOMARKERS FOR STRICTURING (MONTREAL B2) CROHN'S DISEASE
TYPE I, III, AND IV COLLAGEN DEGRADATION FRAGMENTS AND THE TYPE IV COLLAGEN FORMATION/DEGRADATION RATIO ARE SEROLOGICAL BIOMARKERS FOR STRICTURING (MONTREAL B2) CROHN'S DISEASE

Marijn C. Visschedijk  et al.

SEROLOGICAL BIOMARKERS OF TYPE I, III, AND IV COLLAGEN TURNOVER ARE ASSOCIATED WITH THE PRESENCE AND FUTURE PROGRESSION OF STRICTURING AND PENETRATING CROHN'S DISEASE
SEROLOGICAL BIOMARKERS OF TYPE I, III, AND IV COLLAGEN TURNOVER ARE ASSOCIATED WITH THE PRESENCE AND FUTURE PROGRESSION OF STRICTURING AND PENETRATING CROHN'S DISEASE

Marijn C. Visschedijk  et al.

SEROLOGICAL BIOMARKERS OF TYPE III AND IV COLLAGEN REMODELING PREDICT AND MONITOR INFLIXIMAB TREATMENT RESPONSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
SEROLOGICAL BIOMARKERS OF TYPE III AND IV COLLAGEN REMODELING PREDICT AND MONITOR INFLIXIMAB TREATMENT RESPONSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Marijn C. Visschedijk  et al.

BIOMARKERS REFLECTING EXTRACELLULAR MATRIX TURNOVER AND INFLAMMATION CAN BE USED TO MONITOR DISEASE ACTIVITY AND TREATMENT RESPONSE IN PATIENTS WITH CROHN’S DISEASE UNDERGOING INFLIXIMAB INDUCTION THERAPY
BIOMARKERS REFLECTING EXTRACELLULAR MATRIX TURNOVER AND INFLAMMATION CAN BE USED TO MONITOR DISEASE ACTIVITY AND TREATMENT RESPONSE IN PATIENTS WITH CROHN’S DISEASE UNDERGOING INFLIXIMAB INDUCTION THERAPY

Marijn C. Visschedijk  et al.

DIETARY PATTERNS ARE REFLECTED IN THE PLASMA INFLAMMATORY PROTEOME OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE
DIETARY PATTERNS ARE REFLECTED IN THE PLASMA INFLAMMATORY PROTEOME OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Marijn C. Visschedijk  et al.

USE OF TUMOR NECROSIS FACTOR-ALPHA ANTAGONISTS IS ASSOCIATED WITH ATTENUATED IGG ANTIBODY RESPONSE AGAINST SARS-COV-2 IN VACCINATED PATIENTS WITH INFLAMMATORY BOWEL DISEASE
USE OF TUMOR NECROSIS FACTOR-ALPHA ANTAGONISTS IS ASSOCIATED WITH ATTENUATED IGG ANTIBODY RESPONSE AGAINST SARS-COV-2 IN VACCINATED PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Marijn C. Visschedijk  et al.

DISTINCT MUCOSAL HOST-MICROBE INTERACTIONS IN RELATION TO CLINICAL PHENOTYPES IN INFLAMMATORY BOWEL DISEASE
DISTINCT MUCOSAL HOST-MICROBE INTERACTIONS IN RELATION TO CLINICAL PHENOTYPES IN INFLAMMATORY BOWEL DISEASE

Marijn C. Visschedijk  et al.

IN-DEPTH CHARACTERIZATION OF THE SERUM ANTIBODY EPITOPE REPERTOIRE IN INFLAMMATORY BOWEL DISEASE BY HIGH-THROUGHPUT PHAGE-DISPLAYED IMMUNOPRECIPITATION SEQUENCING
IN-DEPTH CHARACTERIZATION OF THE SERUM ANTIBODY EPITOPE REPERTOIRE IN INFLAMMATORY BOWEL DISEASE BY HIGH-THROUGHPUT PHAGE-DISPLAYED IMMUNOPRECIPITATION SEQUENCING

Marijn C. Visschedijk  et al.

THE EFFECT OF PHENOTYPE AND GENOTYPE ON THE PLASMA PROTEOME IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
THE EFFECT OF PHENOTYPE AND GENOTYPE ON THE PLASMA PROTEOME IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Marijn C. Visschedijk  et al.

Item 1 - 17 / 17
1